US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment

被引：5
|
作者：
Reckamp, K. [1 ]
Nieva, J. [2 ]
Taylor, A. [3 ]
Thakrar, B. [3 ]
Wong, J. [4 ]
Potter, D. [3 ]
Bakker, N. [5 ]
Rubinstein, W. [6 ]
Sun, P. [7 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA USA
[3] Astrazeneca, Global Med Affairs, Oncol Business Unit, Global Epidemiol, Cambridge, England
[4] Astrazeneca, Med Evidence & Observat Res Ctr, Global Med Affairs, Gaithersburg, MD USA
[5] Astrazeneca, Oncol Business Unit, Med, Cambridge, England
[6] Cancerlinq Llc, Amer Soc Clin Oncol, Alexandria, VA USA
[7] Astrazeneca, Med Evidence & Observat Res Ctr, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFRm; NSCLC; attrition;
D O I：
10.1016/j.jtho.2019.08.820
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-105
引用
收藏
页码：S402 / S402
页数：1
相关论文
共 50 条
  • [21] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [22] Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC
    Urbanska, Edyta M.
    Grauslund, Morten
    Koffeldt, Peter R.
    Truelsen, Sarah L. B.
    Loefgren, Johan O.
    Costa, Junia C.
    Melchior, Linea C.
    Sorensen, Jens B.
    Santoni-Rugiu, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [23] Associated factors for poor response in advanced EGFR-mutated NSCLC patients under tirosine kinasa inhibitors: Peruvian real-world data.
    Guerrero, Rodrigo Motta
    Aliaga, Carlos
    Gozzer, Thanya Katherine Runciman
    Carracedo, Carlos F.
    Failoc, Virgilio
    Leon, Alejandro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world
    Blondeaux, E.
    Boni, L.
    Chila, G.
    Dri, A.
    Caputo, R.
    Poggio, F.
    Fabi, A.
    Arpino, G.
    Pravisano, F.
    Geuna, E.
    Delucchi, V.
    Ruelle, T.
    Giannubilo, I.
    De Laurentiis, M.
    Puglisi, F.
    Bighin, C.
    Lambertini, M.
    Montemurro, F.
    Del Mastro, L.
    ESMO OPEN, 2025, 10 (02)
  • [25] Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
    Chen, Hsu-Yuan
    Chen, Chia-Hung
    Liao, Wei-Chih
    Lin, Yu-Chao
    Chen, Hung-Jen
    Hsia, Te-Chun
    Cheng, Wen-Chien
    Tu, Chih-Yen
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [26] Treatment of Choice for First-Line Therapy of EGFR-Mutated Stage IIIB Lung Adenocarcinoma Based on the Real World Data
    Lu, S.
    Ye, X.
    Ding, D.
    Li, Z.
    Niu, X.
    Linping, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S619 - S619
  • [27] Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam
    Pham, C. T. M.
    Hoang, T. T. A.
    Truong, P. T.
    Bui, P. T. T.
    Nguyen, T. T.
    Vo, T. N.
    Tran, D. T.
    Nguyen, D. T.
    Tran, T. X.
    Le, H. H.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S662 - S663
  • [28] Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors
    Halmos, Balazs
    Rai, Pragya
    Min, Jae
    Hu, Xiaohan
    Chirovsky, Diana
    Shamoun, Mark
    Zhao, Bin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [29] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [30] Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
    Zhou, J.
    Zhou, J.
    Zheng, J.
    Wang, K.
    Tang, K.
    Lu, D.
    Cui, J.
    Zhu, D.
    Wang, Y.
    Zhao, Y.
    Xing, L.
    Ding, L.
    Shi, X.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1065 - S1065
12345